LETTER TO THE EDITOR

摘要

In the publication, “Public Reimbursement ofPrescription Drugs Used for Off-Label Indicationsin Ontario,”1 my co-author and I identified only onedrug with a serious safety warning directly relatedto a reimbursed off-label use. Our investigation wasinitiated because the Canadian Agency for Drugs andTechnologies in Health had recommended based ona cost-saving perspective that bevacizumab be usedoff-label as the preferred initial therapy for intravitrealtreatment of retinal conditions over the more expensivedrugs of aflibercept and ranibizumab which have regulatoryapproval for the treatment of retinal disorders.